VBLT
Income statement / Annual
Last year (2022), Vascular Biogenics Ltd.'s total revenue was $658,000.00,
a decrease of 14.32% from the previous year.
In 2022, Vascular Biogenics Ltd.'s net income was -$32.22 M.
See Vascular Biogenics Ltd.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$658,000.00 |
$768,000.00 |
$922,000.00 |
$562,000.00 |
$585,000.00 |
$13.86 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$104,000.00
|
$365,000.00
|
$394,000.00
|
$163,000.00
|
$235,000.00
|
$340,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$554,000.00
|
$403,000.00
|
$528,000.00
|
$399,000.00
|
$350,000.00
|
$13.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.84
|
0.52
|
0.57
|
0.71
|
0.6
|
0.98
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$21.65 M
|
$22.70 M
|
$19.66 M
|
$15.47 M
|
$15.94 M
|
$17.77 M
|
$12.45 M
|
$11.20 M
|
$10.97 M
|
$13.51 M
|
General & Administrative Expenses |
$11.75 M
|
$7.70 M
|
$5.36 M
|
$4.83 M
|
$5.15 M
|
$5.80 M
|
$3.79 M
|
$3.64 M
|
$3.77 M
|
$2.41 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$397,000.00
|
$562,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$11.75 M
|
$7.70 M
|
$5.36 M
|
$4.83 M
|
$5.55 M
|
$6.36 M
|
$3.79 M
|
$3.64 M
|
$3.77 M
|
$2.41 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$115,000.00
|
$70,000.00
|
$0.00
|
$42,000.00
|
$34,000.00
|
$33,000.00
|
$43,000.00
|
Operating Expenses |
$33.41 M
|
$30.40 M
|
$25.01 M
|
$20.41 M
|
$21.56 M
|
$24.18 M
|
$16.28 M
|
$14.87 M
|
$14.78 M
|
$15.96 M
|
Cost And Expenses |
$33.51 M
|
$30.76 M
|
$25.41 M
|
$20.58 M
|
$21.79 M
|
$24.52 M
|
$16.28 M
|
$14.87 M
|
$14.78 M
|
$15.96 M
|
Interest Income |
$634,000.00
|
$120,000.00
|
$363,000.00
|
$870,000.00
|
$908,000.00
|
$335,000.00
|
$263,000.00
|
$100,000.00
|
$15,000.00
|
$27,000.00
|
Interest Expense |
$85,000.00
|
$44,000.00
|
$105,000.00
|
$313,000.00
|
$0.00
|
$0.00
|
$0.00
|
$117,000.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$1.69 M
|
$120,000.00
|
$1.56 M
|
$2.58 M
|
$1.16 M
|
$156,000.00
|
$130,000.00
|
$122,000.00
|
$135,000.00
|
$169,000.00
|
EBITDA |
-$31.16 M |
-$29.88 M |
-$22.93 M |
-$17.43 M |
-$19.93 M |
-$10.71 M |
-$16.17 M |
-$14.65 M |
-$14.35 M |
-$16.00 M |
EBITDA Ratio |
-47.36
|
-38.9
|
-24.87
|
-31.01
|
-34.07
|
-0.77
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-49.93
|
-39.06
|
-26.55
|
-35.61
|
-36.25
|
-0.77
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$549,000.00
|
$76,000.00
|
$258,000.00
|
$557,000.00
|
$749,000.00
|
$517,000.00
|
$273,000.00
|
-$17,000.00
|
-$2.63 M
|
-$1.41 M
|
Income Before Tax |
-$32.30 M
|
-$29.92 M
|
-$24.23 M
|
-$19.46 M
|
-$20.46 M
|
-$10.14 M
|
-$16.00 M
|
-$14.89 M
|
-$17.41 M
|
-$17.37 M
|
Income Before Tax Ratio |
-49.09
|
-38.96
|
-26.27
|
-34.62
|
-34.97
|
-0.73
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$85,000.00
|
-$1.21 M
|
$105,000.00
|
$313,000.00
|
-$749,000.00
|
-$517,000.00
|
-$273,000.00
|
$17,000.00
|
$2.63 M
|
$1.41 M
|
Net Income |
-$32.22 M
|
-$28.71 M
|
-$24.33 M
|
-$19.77 M
|
-$20.46 M
|
-$10.14 M
|
-$16.00 M
|
-$14.89 M
|
-$17.41 M
|
-$17.37 M
|
Net Income Ratio |
-48.97
|
-37.38
|
-26.39
|
-35.18
|
-34.97
|
-0.73
|
0
|
0
|
0
|
0
|
EPS |
-0.42 |
-0.41 |
-0.56 |
-0.55 |
-0.62 |
-0.37 |
-0.64 |
-0.73 |
-3.09 |
-1.44 |
EPS Diluted |
-0.42 |
-0.41 |
-0.56 |
-0.55 |
-0.62 |
-0.37 |
-0.64 |
-0.73 |
-3.09 |
-1.44 |
Weighted Average Shares Out |
$77.55 M
|
$69.33 M
|
$43.67 M
|
$35.88 M
|
$32.97 M
|
$27.40 M
|
$24.97 M
|
$20.31 M
|
$5.63 M
|
$12.05 M
|
Weighted Average Shares Out Diluted |
$77.55 M
|
$69.33 M
|
$43.67 M
|
$35.88 M
|
$32.97 M
|
$27.40 M
|
$24.97 M
|
$20.31 M
|
$5.63 M
|
$12.05 M
|
Link |
|
|
|
|
|
|
|
|
|
|